How The Failed Alcon Deal Is Reframing The LENSAR (LNSR) Story And $10 Upside Potential

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.

The updated analyst narrative around LENSAR now centers on a $10 price target that sits above a model fair value of $8.50 per share, giving you a clear reference point for how some on the Street are framing potential upside. Supporters connect this $10 mark to their view that ALLY System adoption can return to patterns seen before the Alcon deal was announced, while skeptics question whether that setup already bakes in optimistic execution. As you read on, you will see how both the bullish and bearish angles shape the evolving story and what that might mean for tracking LENSAR from here.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value LENSAR.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

BTIG shifted LENSAR to Buy from Neutral with a $10 price target, using the prior Alcon acquisition announcement as a reference point for how ALLY System adoption had been trending before the deal was announced. BTIG frames the post deal selloff as a "second chance," implying that the current share price, relative to its $10 target, offers room for potential upside if the ALLY rollout and commercial execution track in line with earlier patterns. Lake Street recently issued an upgrade as well, which supports the view that multiple firms are reassessing the risk or reward balance on LENSAR around similar price levels.

🐻 Bearish Takeaways

The $10 target cited by BTIG and used by other analysts as a reference sits above some internal fair value estimates. This can raise questions about how much execution success is already embedded in that figure. Both BTIG and Lake Street are effectively leaning on historical adoption trends around the ALLY System. If future uptake or deal activity does not resemble that earlier setup, the current valuation arguments could look stretched.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!NasdaqCM:LNSR 1-Year Stock Price Chart

We've flagged 2 risks for LENSAR. See which could impact your investment.

What's in the News

Alcon Research, LLC agreed to acquire LENSAR, Inc. for approximately US$180 million, offering stockholders US$14 per share in cash plus a contingent value right of up to US$2.75 per share in cash. The transaction received approval from the boards of directors of both Alcon and LENSAR and was subject to regulatory clearances, including from the FTC, and approval by LENSAR stockholders. On July 2, 2025, LENSAR stockholders approved the transaction, with 15,983,846 holders voting in favor of the deal. Alcon Research, LLC cancelled the planned acquisition of LENSAR on March 16, 2025. LENSAR had agreed to an US$8.5 million termination fee under certain conditions, while Wells Fargo Securities, LLC was set to receive an estimated US$7.5 million fee tied in part to deal completion.

Story Continues

How This Changes the Fair Value For LENSAR

Fair value in the model remains at US$8.50 per share, with no change to the central estimate. The assumed revenue growth rate stays at about 26.22%, with no adjustment. The net profit margin assumption remains about 8.51%, unchanged in the model. The future P/E multiple moves from about 13.82x to 13.87x in the updated inputs. The discount rate shifts from 7.75% to about 7.88% in the latest model run.

Never Miss an Update: Follow The Narrative

Narratives connect a company’s real world story to a set of forward looking assumptions, forecasts, and a fair value estimate. They evolve as fresh results, analyst views, and corporate events come through.

Head over to the Simply Wall St Community and follow the Narrative on LENSAR to stay up to date on:

How ALLY System placements, procedure volumes, and a growing contract pipeline in markets like Europe and Southeast Asia feed into the revenue story. What analysts are assuming about the ramp up of new systems, future revenue changes, and the shift in profit margins over the next few years. Key risks around competition from larger ophthalmic peers, reliance on distributor led international expansion, and earnings volatility tied to warrant liabilities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include LNSR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments